ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

Eveline A. van de Stadt; Maqsood Yaqub; Idris Bahce; N. H. Hendrikse

doi:https://doi.org/10.2967/jnumed.119.235705

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

Eveline A. van de Stadt, Maqsood Yaqub, Idris Bahce, N. H. Hendrikse

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	305
Number of pages	1
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume	61
Issue number	2
Early online date	4 Oct 2019
DOIs	https://doi.org/10.2967/jnumed.119.235705
Publication status	Published - 1 Feb 2020

Access to Document

https://doi.org/10.2967/jnumed.119.235705

Cite this

@article{dea55cbda3b84abbb8e4bb061a3eb111,

title = "ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases",

author = "{van de Stadt}, {Eveline A.} and Maqsood Yaqub and Idris Bahce and Hendrikse, {N. H.}",

year = "2020",

month = feb,

day = "1",

doi = "https://doi.org/10.2967/jnumed.119.235705",

language = "English",

volume = "61",

pages = "305",

journal = "Journal of nuclear medicine : official publication, Society of Nuclear Medicine",

issn = "1535-5667",

publisher = "Society of Nuclear Medicine Inc.",

number = "2",

}

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases. / van de Stadt, Eveline A.; Yaqub, Maqsood ; Bahce, Idris et al.
In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 61, No. 2, 01.02.2020, p. 305.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib

T2 - Clinical Implications in the Treatment of Central Nervous System Metastases

AU - van de Stadt, Eveline A.

AU - Yaqub, Maqsood

AU - Bahce, Idris

AU - Hendrikse, N. H.

PY - 2020/2/1

Y1 - 2020/2/1

UR - http://www.scopus.com/inward/record.url?scp=85079020980&partnerID=8YFLogxK

U2 - https://doi.org/10.2967/jnumed.119.235705

DO - https://doi.org/10.2967/jnumed.119.235705

M3 - Letter

C2 - 31586007

SN - 1535-5667

VL - 61

SP - 305

JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine

IS - 2

ER -

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

Access to Document

Other files and links

Cite this